S Herschorn

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi The contemporary role of Burch colposuspension
    Jerome Green
    Division of Urology, University of Toronto, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Curr Opin Urol 15:250-5. 2005
  2. ncbi S-shaped coaxial dilators for male urethral strictures
    Sender Herschorn
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Urology 69:1199-201. 2007
  3. ncbi A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey
    Sender Herschorn
    Division of Urology, University of Toronto, Toronto, Ontario, Canada
    BJU Int 101:52-8. 2008
  4. ncbi Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial
    Sender Herschorn
    Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Room A309, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada
    J Urol 185:2229-35. 2011
  5. ncbi The use of biological and synthetic materials in vaginal surgery for prolapse
    Sender Herschorn
    Division of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Urol 17:408-14. 2007
  6. ncbi Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies
    Sender Herschorn
    Sunnybrook Health Sciences Centre, Division of Urology, Toronto, Ontario, Canada
    Urology 75:1149-55. 2010
  7. ncbi Surgical treatment of stress incontinence in men
    Sender Herschorn
    University of Toronto, Sunnybrook Health Sciences Centre, Room A309, 2075 Bayview Avenue, Toronto, ON M4N3M5 Canada
    Neurourol Urodyn 29:179-90. 2010
  8. ncbi Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial
    Sender Herschorn
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, Ontario, Canada
    BJU Int 105:58-66. 2010
  9. ncbi Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial
    Sender Herschorn
    Department of Surgery Urology, University of Toronto, Toronto, Ontario, Canada
    J Urol 183:1892-8. 2010
  10. ncbi Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (? 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study
    S Herschorn
    University of Toronto, Department of Surgery Urology, Toronto, Canada
    Curr Med Res Opin 27:375-82. 2011

Detail Information

Publications22

  1. ncbi The contemporary role of Burch colposuspension
    Jerome Green
    Division of Urology, University of Toronto, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Curr Opin Urol 15:250-5. 2005
    ..At this point, tension-free vaginal tape appears to be at least equivalent to the Burch colposuspension and, with longer follow-up studies, may challenge its role as a gold standard surgical treatment for female stress incontinence...
  2. ncbi S-shaped coaxial dilators for male urethral strictures
    Sender Herschorn
    Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Urology 69:1199-201. 2007
    ..To facilitate stricture dilatation and minimize trauma a new S-shaped coaxial urethral dilator was designed. Prototypes were tested, and the final design was devised with a technique for successful insertion...
  3. ncbi A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey
    Sender Herschorn
    Division of Urology, University of Toronto, Toronto, Ontario, Canada
    BJU Int 101:52-8. 2008
    ..To ascertain the prevalence of lower urinary tract symptoms (LUTS) and urinary incontinence (UI) in Canada, using a cross-Canada telephone survey, as there is a wide discrepancy in the reported prevalence of these conditions...
  4. ncbi Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial
    Sender Herschorn
    Division of Urology, University of Toronto, Sunnybrook Health Sciences Centre, Room A309, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada
    J Urol 185:2229-35. 2011
    ..We determined the efficacy of onabotulinumtoxinA for neurogenic detrusor overactivity secondary to spinal cord injury or multiple sclerosis...
  5. ncbi The use of biological and synthetic materials in vaginal surgery for prolapse
    Sender Herschorn
    Division of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Urol 17:408-14. 2007
    ..This article reviews the currently available biological and synthetic graft materials available for pelvic prolapse. It also focuses on recent publications examining their use in transvaginal prolapse surgery...
  6. ncbi Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies
    Sender Herschorn
    Sunnybrook Health Sciences Centre, Division of Urology, Toronto, Ontario, Canada
    Urology 75:1149-55. 2010
    ..To assess the efficacy, safety, and tolerability of fesoterodine 4 and 8 mg in men with overactive bladder...
  7. ncbi Surgical treatment of stress incontinence in men
    Sender Herschorn
    University of Toronto, Sunnybrook Health Sciences Centre, Room A309, 2075 Bayview Avenue, Toronto, ON M4N3M5 Canada
    Neurourol Urodyn 29:179-90. 2010
    ..The committee was charged with the responsibility of reviewing and evaluating all published data relating to surgical treatment of male urinary incontinence since the previous consultation in 2004...
  8. ncbi Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial
    Sender Herschorn
    Sunnybrook Health Sciences Centre, Division of Urology, University of Toronto, Toronto, Ontario, Canada
    BJU Int 105:58-66. 2010
    ..To compare the efficacy and tolerability of fesoterodine 8 mg with tolterodine extended-release (ER) 4 mg and placebo in a randomized clinical trial of patients with an overactive bladder (OAB)...
  9. ncbi Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial
    Sender Herschorn
    Department of Surgery Urology, University of Toronto, Toronto, Ontario, Canada
    J Urol 183:1892-8. 2010
    ..Of available antimuscarinics oxybutynin is associated with the highest dry mouth rate. We compared the safety and tolerability of 5 mg solifenacin vs 15 mg oxybutynin immediate release...
  10. ncbi Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (? 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study
    S Herschorn
    University of Toronto, Department of Surgery Urology, Toronto, Canada
    Curr Med Res Opin 27:375-82. 2011
    ....
  11. ncbi Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*
    Sender Herschorn
    Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada
    Curr Med Res Opin 24:3513-21. 2008
    ..Research design and methods: Subjects with overactive bladder (OAB) were randomized to receive tolterodine ER (4 mg) or placebo for 12 weeks. This double-blind study is registered with ClinicalTrials.gov (identifier: NCT00143377)...
  12. ncbi Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder
    S Herschorn
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Med Econ 13:508-15. 2010
    ..To estimate the cost effectiveness of solifenacin 5?mg/day compared to oxybutynin immediate-release (IR) 15?mg/day in patients with overactive bladder, from the perspective of the Canadian healthcare (payer) system...
  13. ncbi Impact of a health education intervention in overactive bladder patients
    Sender Herschorn
    Sunnybrook Health and Women's College Health Sciences Centre, Toronto, Ontario, Canada
    Can J Urol 11:2430-7. 2004
    ..It also resulted in a significantly increased use of behavior modification therapies and better self-perception of treatment outcome...
  14. ncbi Current status of injectable agents for female stress urinary incontinence
    S Herschorn
    Division of Urology, University of Toronto, Sunnybrook and Women's Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Can J Urol 8:1281-9. 2001
    ..The indication for injectables is intrinsic sphincter deficiency but hypermobility is not a contraindication. Long-term durability, cost effectiveness, and some safety issues still have to be addressed by further clinical trials...
  15. ncbi Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma
    Richard Choo
    Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 53:290-6. 2002
    ..To quantify the effect of radiotherapy (RT) on urodynamics at 18 months post-therapy, using urodynamic study, in prostate cancer patients undergoing definitive external beam RT...
  16. ncbi Current role of injectable agents for female stress urinary incontinence
    Sender Herschorn
    Division of Urology, University of Toronto, Sunnybrook and Women's Health Sciences Centre, Toronto, Ontario, Canada
    Can J Urol 13:5-12. 2006
    ..The definite superiority of one agent over another has not yet been established...
  17. ncbi Canadian guidelines for the management of benign prostatic hyperplasia
    J Curtis Nickel
    Department of Urology, Queen's University, Kingston General Hospital, Ontario, Canada
    Can J Urol 12:2677-83. 2005
    ..CONCLUSIONS: Diagnostic and treatment guidelines for BPH reflect the Canadian social priorities, economics, socialized medical practice, manpower issues, and medicolegal considerations...
  18. ncbi Symptom bother and health care-seeking behavior among individuals with overactive bladder
    Debra E Irwin
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    Eur Urol 53:1029-37. 2008
    ..To estimate symptom bother and health care seeking among individuals with overactive bladder (OAB; ie, cases) using current International Continence Society definitions...
  19. ncbi Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study
    Debra E Irwin
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, United States
    Eur Urol 50:1306-14; discussion 1314-5. 2006
    ..Estimate the prevalence of urinary incontinence (UI), overactive bladder (OAB), and other lower urinary tract symptoms (LUTS) among men and women in five countries using the 2002 International Continence Society (ICS) definitions...
  20. ncbi Urethral injections for female stress incontinence
    Rodney A Appell
    Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    BJU Int 98:27-30; discussion 31. 2006
    ..As these materials develop, understanding of the preferred injection technique also is being gained. The delivery method and site might prove to substantially alter the biological activity of these compounds...
  21. ncbi Examining lower urinary tract symptom constellations using cluster analysis
    Karin S Coyne
    Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA
    BJU Int 101:1267-73. 2008
    ..To gain a better understanding of how patients experience lower urinary tract symptoms (LUTS) and to determine whether particular symptoms cluster together, as LUTS seldom occur alone...
  22. ncbi Understanding the elements of overactive bladder: questions raised by the EPIC study
    Debra E Irwin
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599, USA
    BJU Int 101:1381-7. 2008
    ....